Acute Myeloid Leukemia News and Research

RSS
Acute Myeloid Leukemia (AML) is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.
Study recommends treatment change for pre-leukemia disease

Study recommends treatment change for pre-leukemia disease

Decitabine improves myelodysplastic syndrome treatment

Decitabine improves myelodysplastic syndrome treatment

Decitabine improves patient outcomes in myelodysplastic syndromes

Decitabine improves patient outcomes in myelodysplastic syndromes

Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease

Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease

Acute-leukemia sign may signal need for different therapy

Acute-leukemia sign may signal need for different therapy

Discovery of new gene FANCM sheds light on repair of damaged DNA

Discovery of new gene FANCM sheds light on repair of damaged DNA

Data directly support a pathogenetic model of acute leukemia

Data directly support a pathogenetic model of acute leukemia

Long-term outcomes studied for stem cell transplant recipients

Long-term outcomes studied for stem cell transplant recipients

Giving children access to drug clinical trials is crucial, clofarabine approval shows

Giving children access to drug clinical trials is crucial, clofarabine approval shows

Enzyme that helps trigger the development of leukemia

Enzyme that helps trigger the development of leukemia

Certain leukemia oncogenes switch on genetic programs that govern self-renewal, a unique stem cell characteristic

Certain leukemia oncogenes switch on genetic programs that govern self-renewal, a unique stem cell characteristic

Genetic mutations and cellular modifications may provide clues to the associations between slight genetic abnormalities and often fatal diseases

Genetic mutations and cellular modifications may provide clues to the associations between slight genetic abnormalities and often fatal diseases

Data from phase II study of Trisenox (arsenic trioxide) injection in myelodysplasia

Data from phase II study of Trisenox (arsenic trioxide) injection in myelodysplasia

Lorus Therapeutics allowed Canadian patent to protect anticancer drugs

Lorus Therapeutics allowed Canadian patent to protect anticancer drugs

Maxim Pharmaceuticals to withdraw NDA for advanced malignant melanoma

Maxim Pharmaceuticals to withdraw NDA for advanced malignant melanoma

Experimental drug PKC412 may be the key to treating myeloproliferative disease

Experimental drug PKC412 may be the key to treating myeloproliferative disease

Data suggests potential role of Quadramet in conjunction with chemotherapy for the treatment of acute myeloid leukemia

Data suggests potential role of Quadramet in conjunction with chemotherapy for the treatment of acute myeloid leukemia

Guidelines for determining the best possible time to receive bone marrow transplants

Guidelines for determining the best possible time to receive bone marrow transplants

Smoking a lot more harmful than previously thought

Smoking a lot more harmful than previously thought

Smoking causes diseases in nearly every organ of the body

Smoking causes diseases in nearly every organ of the body

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.